Tongue-delivered solution for MS sufferers
Cambridge Consultants has worked with US company Helius Medical Technologies to develop a breakthrough technology to treat patients suffering from neurological disease, such as MS.
The device, known as the Portable Neuromodulation Stimulator (PoNS™), is the first commercial product from Nasdaq-quoted Helius and is designed to deliver potentially life-changing therapy via the tongue.
MS is a chronic, degenerative and debilitating disease estimated to affect approximately one million patients in the US. MS patients can have restriction of mobility, balance, and gait, and can struggle to stand or walk on their own. There has been a lack of access to effective solutions until now.
The PoNS technology, developed for Pennsylvania-based Helius by Cambridge Consultants, is a non-invasive, body-worn medical device that delivers controlled neurostimulation to two cranial nerves via the tongue.
It is the first and only tongue-delivered neuromodulation therapy. When used in conjunction with physical therapy, PoNS Treatment is believed to enhance a patient’s neuroplasticity – the brain’s ability to restructure or relearn new functions.
Enhanced neuroplasticity improves a patient’s ability to learn, train, and rehabilitate. Patients in the US suffering from gait deficit due to mild-to-moderate symptoms from MS can benefit from PoNS treatment, which has the potential to improve, or even restore, their ability to walk.
Cambridge Consultants has provided Helius with design and development services for the past four years, delivering world-class systems and expertise for the PoNS device.
Rahul Sathe, Head of Medical Innovation, Cambridge Consultants, said: “The development collaboration between Helius and Cambridge Consultants has been built on commercial vision, clinical science, product innovation, and technology expertise.
“These are the ingredients enabling us to create world-changing innovation and products that transform our clients’ businesses. We congratulate Helius on their milestone achievement to deliver life-changing therapy to significantly underserved MS patients.”
Dane Andreeff, Interim President and Chief Executive Officer of Helius, added: “The PoNS device is now the first, and only, medical device cleared in the U.S. for this indication. This milestone represents the most important achievement of our organisation.
“I would like to take this opportunity to thank Cambridge Consultants for their contributions. Their team successfully delivered the unique combination of disciplines and expertise required to complete our project.
“The result of these efforts, our PoNS device, has the potential to significantly improve the ability of MS patients to walk and as a result may enhance their safety and quality of life.”